A Randomized, International, Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib

Trial Profile

A Randomized, International, Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Adenocarcinoma; Thyroid cancer
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca; Sanofi Genzyme
  • Most Recent Events

    • 07 Jul 2017 Planned End Date changed from 1 Dec 2017 to 14 Mar 2018.
    • 19 Jan 2017 This trial has been completed in Belgium as per European Clinical Trials Database.
    • 05 Jan 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top